XML 22 R11.htm IDEA: XBRL DOCUMENT v3.22.1
Stockholders' Equity
 3 Months Ended
Mar. 31, 2022
Equity [Abstract]  
Stockholders' Equity Stockholders' Equity
Common Stock
The Company had the following transactions in its common stock during the three months ended March 31, 2022:
•In January 2022, the Company issued 72,152 shares of Class A common stock for no additional consideration upon conversion of 10,149 shares of Series C Preferred Stock and 78,674 of Series D Preferred Stock.
•In March 2022, the Company issued 39,386 shares of Class A common stock for services with a value of $99,252.
•On January 13, 2022 the Company amended the Corporation's Amended and Restated Certificate of Incorporation increasing the authorized capital stock from 195,000,000 to 295,000,000.
Stock Options
The following summarizes the stock option activity for the three months ended March 31, 2022:
OptionsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Life (Years)
Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
1,790,000 $0.19 6.09$3,098,055 
Granted— 
Forfeited(618,000)0.30 
Exercised— 
Outstanding at March 31, 2022
1,172,000 $0.13 6.17$1,075,950 
Vested and expected to vest at March 31, 2022
1,172,000 $0.13 6.17$1,075,950 
Exercisable at March 31, 2022
1,071,125 $0.14 6.14$975,341 
The following table summarizes information about options outstanding and exercisable as of March 31, 2022:
Options OutstandingOptions Exercisable
Exercise
Price		Number
of Shares		Weighted
Average
Remaining
Life (Years)		Weighted
Average
Exercise
Price		Number
of Shares		Weighted
Average
Exercise
Price
$0.05 979,000 6.38$0.05 883,437 $0.05 
0.10 85,000 6.280.10 79,688 0.10 
0.90 108,000 5.270.90 108,000 0.90 
1,172,000 1,071,125 
During the three months ended March 31, 2022 and 2021, stock option expense amounted to $1,026 and $19,341, respectively. Unrecognized stock option expense as of March 31, 2022, amounted to $6,184, which will be recognized over a period extending through December 2022.
Warrants
The following summarizes the warrants activity for the three months ended March 31, 2022:
WarrantsWeighted-
Average
Exercise
Price		Weighted-
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding at December 31, 2021
5,527,778 $3.32 4.62$— 
Granted— 
Forfeited— 
Exercised— 
Outstanding at March 31, 2022
5,527,778 $3.32 4.38$— 
Vested and expected to vest at March 31, 2022
5,527,778 $3.32 4.38$— 
Exercisable at March 31, 2022
5,099,207 $3.34 4.38$— 
The following table summarizes information about warrants outstanding and exercisable as of March 31, 2022:
Warrants OutstandingWarrants Exercisable
Exercise
Price		Number
of Shares		Weighted
Average
Remaining
Life (Years)		Weighted
Average
Exercise
Price		Number
of Shares		Weighted
Average
Exercise
Price
 
$6.60 416,667 2.89$6.60 416,667 $6.60 
2.52 396,825 2.702.52 396,825 2.52
3.10 4,285,715 4.653.10 4,285,715 3.10
3.09 428,571 4.653.08 — 
 5,527,778 5,099,207 

During the year ended December 31, 2021, the Company issued 416,667 warrants to a placement agent in connection with sale of its common stock The warrants have an exercise price of $6.60, are exercisable as of August 16, 2021 and expire on February 16, 2025. The Company issued another 428,571 warrants to a placement agent in connection with the sale of its common stock. The warrants have an exercise price of $3.08, are exercisable as of May 26, 2022, and expire November 22, 2026. The Company issued another 396,825 warrants in connection to the RCA acquisition. The warrants have an exercise price of $2.52, were exercisable as of December 9, 2021, and expire December 9, 2024.

The fair value of the 416,667, the 428,571, and the 396,825 warrants issued to the placement agent and RCA sellers during the year ended December 31, 2021, are $2,498,637, $902,414, and $668,863 respectively and was determined using the Black-Scholes option pricing model with the following assumptions:

Stock price
$2.51-$7.03
Risk-free interest rate
0.01%-1.02%
Expected life of the options
2-5 years
Expected volatility
159-347%
Expected dividend yield0%
The fair value of the warrants was recorded as offering costs with a corresponding credit to additional paid in capital.